Publicaciones en colaboración con investigadores/as de Ohio State University (16)

2024

  1. A plain language summary of publication of the efficacy and safety of individualized niraparib dosing based on baseline body weight and platelet count in the PRIMA/ENGOT-OV26/GOG-3012 trial

    Future Oncology, Vol. 20, Núm. 13, pp. 799-809

  2. Niraparib Population Pharmacokinetics and Exposure-Response Relationships in Patients With Newly Diagnosed Advanced Ovarian Cancer

    Clinical Therapeutics, Vol. 46, Núm. 8, pp. 612-621

  3. PD-1H/VISTA mediates immune evasion in acute myeloid leukemia

    The Journal of clinical investigation, Vol. 134, Núm. 3

  4. Patterns of initial ovarian cancer recurrence on niraparib maintenance monotherapy in patients with no baseline evidence of disease after first-line chemotherapy: An ad hoc subgroup analysis of PRIMA/ENGOT-OV26/GOG-3012

    Gynecologic Oncology, Vol. 189, pp. 68-74

  5. Progression-free survival and safety at 3.5 years of follow-up: results from the randomized phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer–a plain language summary

    Future Oncology, Vol. 20, Núm. 22, pp. 1531-1544

2023

  1. Progression-free survival and safety at 3.5 years of follow-up: results from the randomised phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer

    European Journal of Cancer, Vol. 189

2022

  1. Quality-adjusted time without symptoms of disease or toxicity and quality-adjusted progression-free survival with niraparib maintenance in first-line ovarian cancer in the PRIMA trial

    Therapeutic Advances in Medical Oncology, Vol. 14

2020

  1. Niraparib in Patients With Newly Diagnosed Advanced Ovarian Cancer

    Obstetrical and Gynecological Survey

  2. Phase Ib study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer

    Gynecologic Oncology, Vol. 157, Núm. 2, pp. 379-385

2019

  1. Niraparib in patients with newly diagnosed advanced ovarian cancer

    New England Journal of Medicine, Vol. 381, Núm. 25, pp. 2391-2402

2018

  1. Safety and activity findings from a phase 1b escalation study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with carboplatin in patients with platinum-sensitive ovarian cancer

    Gynecologic Oncology, Vol. 151, Núm. 1, pp. 46-52

1999

  1. Intraoperative high dose rate brachytherapy can be used to salvage patients with previously irradiated head and neck recurrences.

    Revista de medicina de la Universidad de Navarra, Vol. 43, Núm. 2, pp. 56-61

  2. Iodine-125 brachytherapy in the treatment of colorectal adenocarcinoma metastatic to the liver

    Cancer, Vol. 85, Núm. 6, pp. 1218-1225

1998

  1. Interstitial brachytherapy in the management of primary carcinoma of the cervix and vagina

    Gynecologic Oncology, Vol. 70, Núm. 1, pp. 27-32

  2. Intraoperative electron beam radiotherapy for previously irradiated advanced head and neck malignancies

    International Journal of Radiation Oncology Biology Physics, Vol. 42, Núm. 5, pp. 1085-1089

1997

  1. Pulmonary embolization of permanently implanted radioactive palladium- 103 seeds for carcinoma of the prostate

    International Journal of Radiation Oncology Biology Physics, Vol. 39, Núm. 3, pp. 667-670